Overview

HC-1119 Adjuvant Treatment for Hospitalized COVID-19 Patients

Status:
Not yet recruiting
Trial end date:
2021-11-15
Target enrollment:
Participant gender:
Summary
The primary purpose of this study is to evaluate the efficacy of HC-1119 as an adjuvant treatment for hospitalized COVID-19 male and female patients.
Phase:
Phase 3
Details
Lead Sponsor:
Applied Biology, Inc.
Collaborator:
Hinova Pharmaceuticals Inc.